We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Are Medical Stocks Lagging Amedisys (AMED) This Year?
Read MoreHide Full Article
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Is Amedisys (AMED - Free Report) one of those stocks right now? Let's take a closer look at the stock's year-to-date performance to find out.
Amedisys is one of 997 companies in the Medical group. The Medical group currently sits at #5 within the Zacks Sector Rank. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.
The Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks. This system has a long record of success, and these stocks tend to be on track to beat the market over the next one to three months. Amedisys is currently sporting a Zacks Rank of #2 (Buy).
The Zacks Consensus Estimate for AMED's full-year earnings has moved 1.5% higher within the past quarter. This signals that analyst sentiment is improving and the stock's earnings outlook is more positive.
Based on the most recent data, AMED has returned 3.1% so far this year. At the same time, Medical stocks have lost an average of 6.8%. As we can see, Amedisys is performing better than its sector in the calendar year.
BrightSpring Health Services, Inc. (BTSG - Free Report) is another Medical stock that has outperformed the sector so far this year. Since the beginning of the year, the stock has returned 34.6%.
For BrightSpring Health Services, Inc. the consensus EPS estimate for the current year has increased 23.8% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Looking more specifically, Amedisys belongs to the Medical - Outpatient and Home Healthcare industry, which includes 17 individual stocks and currently sits at #73 in the Zacks Industry Rank. On average, stocks in this group have gained 2.6% this year, meaning that AMED is performing better in terms of year-to-date returns.
BrightSpring Health Services, Inc. however, belongs to the Medical Services industry. Currently, this 58-stock industry is ranked #65. The industry has moved -5.5% so far this year.
Investors interested in the Medical sector may want to keep a close eye on Amedisys and BrightSpring Health Services, Inc. as they attempt to continue their solid performance.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Are Medical Stocks Lagging Amedisys (AMED) This Year?
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Is Amedisys (AMED - Free Report) one of those stocks right now? Let's take a closer look at the stock's year-to-date performance to find out.
Amedisys is one of 997 companies in the Medical group. The Medical group currently sits at #5 within the Zacks Sector Rank. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.
The Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks. This system has a long record of success, and these stocks tend to be on track to beat the market over the next one to three months. Amedisys is currently sporting a Zacks Rank of #2 (Buy).
The Zacks Consensus Estimate for AMED's full-year earnings has moved 1.5% higher within the past quarter. This signals that analyst sentiment is improving and the stock's earnings outlook is more positive.
Based on the most recent data, AMED has returned 3.1% so far this year. At the same time, Medical stocks have lost an average of 6.8%. As we can see, Amedisys is performing better than its sector in the calendar year.
BrightSpring Health Services, Inc. (BTSG - Free Report) is another Medical stock that has outperformed the sector so far this year. Since the beginning of the year, the stock has returned 34.6%.
For BrightSpring Health Services, Inc. the consensus EPS estimate for the current year has increased 23.8% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Looking more specifically, Amedisys belongs to the Medical - Outpatient and Home Healthcare industry, which includes 17 individual stocks and currently sits at #73 in the Zacks Industry Rank. On average, stocks in this group have gained 2.6% this year, meaning that AMED is performing better in terms of year-to-date returns.
BrightSpring Health Services, Inc. however, belongs to the Medical Services industry. Currently, this 58-stock industry is ranked #65. The industry has moved -5.5% so far this year.
Investors interested in the Medical sector may want to keep a close eye on Amedisys and BrightSpring Health Services, Inc. as they attempt to continue their solid performance.